KIF2C: An important factor involved in signaling pathways, immune infiltration, and DNA damage repair in tumorigenesis

被引:5
|
作者
Li, Rui-Qing [1 ]
Yang, Yan [2 ]
Qiao, Lin [1 ]
Yang, Li [1 ,3 ]
Shen, Dan -Dan [1 ]
Zhao, Xiao-Jing [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Zhengzhou, Peoples R China
[2] Xinxiang Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xinxiang, Peoples R China
[3] Zhengzhou Key Lab Endometrial Dis Prevent & Treatm, Zhengzhou, Peoples R China
关键词
KIF2C; Tumorigenesis; Signaling pathways; Immune infiltration; DNA damage repair; Chemotherapy resistance; CENTROMERE-ASSOCIATED KINESIN; CHROMOSOMAL INSTABILITY; HUB GENES; MCAK; CANCER; IDENTIFICATION; RESISTANCE; PROGNOSIS; FAMILY; BIOINFORMATICS;
D O I
10.1016/j.biopha.2024.116173
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Backgrounds: Poorly regulated mitosis and chromosomal instability are common characteristics in malignant tumor cells. Kinesin family member 2 C (KIF2C), also known as mitotic centromere-associated kinesin (MCAK) is an essential component during mitotic regulation. In recent years, KIF2C was shown to be dysregulated in several tumors and was involved in many aspects of tumor self -regulation. Research on KIF2C may be a new direction and target for anti -tumor therapy. Object: The article aims at reviewing current literatures and summarizing the research status of KIF2C in malignant tumors as well as the oncogenic signaling pathways associated with KIF2C and its role in immune infiltration. Result: In this review, we summarize the KIF2C mechanisms and signaling pathways in different malignant tumors, and briefly describe its involvement in pathways related to classical chemotherapeutic drug resistance, such as MEK/ERK, mTOR, Wnt/8-catenin, P53 and TGF-81/Smad pathways. KIF2C upregulation was shown to promote tumor cell migration, invasion, chemotherapy resistance and inhibit DNA damage repair. It was also highly correlated with microRNAs, and CD4 +T cell and CD8 +T cell tumor immune infiltration. Conclusion: This review shows that KIF2C may function as a new anticancer drug target with great potential for malignant tumor treatment and the mitigation of chemotherapy resistance.
引用
收藏
页数:9
相关论文
共 7 条
  • [1] KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer
    Liu, Shanshan
    Ye, Ziwei
    Xue, Vivian Weiwen
    Sun, Qi
    Li, Huan
    Lu, Desheng
    BMC CANCER, 2023, 23 (01)
  • [2] KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer
    Shanshan Liu
    Ziwei Ye
    Vivian Weiwen Xue
    Qi Sun
    Huan Li
    Desheng Lu
    BMC Cancer, 23
  • [3] KIF2C Is a Novel Prognostic Biomarker and Correlated with Immune Infiltration in Endometrial Cancer
    An, Lanfen
    Zhang, Jun
    Feng, Dilu
    Zhao, Yingchao
    Ouyang, Weixiang
    Shi, Rui
    Zhou, Xing
    Yu, Zhicheng
    Wei, Sitian
    Min, Jie
    Wang, Hongbo
    STEM CELLS INTERNATIONAL, 2021, 2021
  • [4] Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD
    Xiong, Jianghui
    Wu, Rongshou
    He, Aoxiao
    Hou, Ping
    Wang, Jiakun
    Zhang, Rongguiyi
    Liao, Wenjun
    Wu, Linquan
    Li, Enliang
    TISSUE & CELL, 2022, 78
  • [5] Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD
    Xiong, Jianghui
    Wu, Rongshou
    He, Aoxiao
    Hou, Ping
    Wang, Jiakun
    Zhang, Rongguiyi
    Liao, Wenjun
    Wu, Linquan
    Li, Enliang
    TISSUE & CELL, 2022, 78
  • [6] Kinesin Kif2C in regulation of DNA double strand break dynamics and repair
    Zhu, Songli
    Paydar, Mohammadjavad
    Wang, Feifei
    Li, Yanqiu
    Wang, Ling
    Barrette, Benoit
    Bessho, Tadayoshi
    Kwok, Benjamin H.
    Peng, Aimin
    ELIFE, 2020, 9
  • [7] Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer
    Zhang, Pingxin
    Gao, Hang
    Ye, Chunwei
    Yan, Ruping
    Yu, Lu
    Xia, Chengxing
    Yang, Delin
    FRONTIERS IN IMMUNOLOGY, 2022, 13